The future of TKR-targeted therapies lies in addressing the aforementioned challenges. This includes: - Combination therapies: Using a combination of different drugs to target multiple pathways simultaneously can help overcome resistance. - Biomarker development: Identifying reliable biomarkers can help predict which patients will respond to specific TKR-targeted therapies. - Next-generation inhibitors: Developing inhibitors that can target resistant mutations or multiple kinases simultaneously. - Personalized medicine: Tailoring treatments based on the genetic and molecular profile of an individual's tumor.
